Kalvista Pharmaceuticals, Inc. · NASDAQ:KALV
Kalvista Pharmaceuticals — 2026 HAEi Regional Conference Americas
11 slides from Kalvista Pharmaceuticals's conference presentation, October 2026
Slide 1: Improvement in Health-related Quality of Life With Sebetralstat: KONFIDENT-S Results
Improvement in Health-related Quality of Life With Sebetralstat for On-demand Treatment of Hereditary Angioedema Attacks: Results From the KONFIDENT-S Study Stratified by Number of Treated Attacks Presenter: William Lumry1 Emel Aygören-Pürsün,2 Aleena Banerji,3,4 Jonathan A. Bernstein,5 Danny M. Coh
Slide 2: Disclosures
Disclosures • Dr. William Lumry declares the following, real or perceived, conflicts of interest: ‒ Receipt of grants/research support, honoraria, or consultation fees: KalVista Pharmaceuticals, Astria, BioCryst, BioMarin, CSL Behring, Express Scripts/CVS, Fresenius Kabi, Intellia, Magellan, Optum,
Slide 3: Background and Objective
Background and Objective HAE is characterized by unpredictable, painful, and debilitating attacks that impair HRQoL1 Greater reductions in HRQoL are observed when treatment is delayed or attacks are not treated2 Sebetralstat is the first and only oral on-demand therapy approved for patients with HAE
Slide 4: KONFIDENT-S Study Design
KONFIDENT-S Study Design • Eligible participants were ≥12 years of age with HAE- C1INH and had ≥2 documented attacks within 3 Treatment Period (0-24 months) months, or had completed the phase 3 KONFIDENT trial1 End Monthly Quarterly of • Participants self-administered sebetralstat visits visits stud
Slide 5: Participant Demographics
Participant Demographics N=138 Age, mean (range), years 36.2 (12-77) Sex, female, n (%) 90 (65) Race, n (%)a White 103 (75) Asian 17 (12) 126 participants Other or Multiple 11 (8) reported AE-QoL outcomes (21 adolescents and 105 adults) BMI, median (IQR), kg/m2 25.4 (22-31) HAE-C1INH-Type 1, n (%) 1
Slide 6: Sebetralstat-treated Attack Characteristics
Sebetralstat-treated Attack Characteristics Sebetralstat-treated Attacks n=2469 Number of attacks per month, median (IQR) 1.04 (0.53-1.79) Baseline pooled primary attack location, n (%)a Mucosal 1028 (44) Laryngeal 49 (2) Subcutaneous 1313 (56) Baseline PGI-S rating, n (%)b Mildc 913 (39) Moderate 9
Slide 7: AE-QoL Improved From Baseline Regardless of Attack Frequency
AE-QoL Improved From Baseline to Month 15 With Sebetralstat Treatment Regardless of Attack Frequency 60 50 For all participants in KONFIDENT-S, the locally estimated scatterplot smoothing AE-QoL, Mean Score 44.7 ∆ −12.7 40 (LOESS) fitted AE-QoL total score decreased 35.9 from 35.9 at baseline to 28.
Slide 8: Clinically Meaningful (≥6-Point) Improvements in AE-QoL
Clinically Meaningful (≥6-Point) Improvements in AE-QoL Were Achieved Regardless of Attack Frequency 100 Q1 (≤0.53 attacks/month) 90 Q4 (>1.79 attacks/month) With AE-QoL Reduction ≥6, % 80 Overall Proportion of Participants 70 60 61.4 At Month 15, 45.2% of participants 50 achieved the MCID, a ≥6-poi
Slide 9: AE-QoL Improved Across Domains
AE-QoL Improved From Baseline to Month 15 With Sebetralstat Treatment Across Domains Functioning Fears/Shame Domain: Fears/Shame, Mean Score 60 60 Domain: Functioning, Mean Score 53.8 Q1 (≤0.53 attacks/month) 50 47.4 50 ∆ −18.6 ∆ −19.6 42.9 Q4 (>1.79 attacks/month) 40 40 35.2 Overall 30 33.2 30 33.2
Slide 10: Conclusions
Conclusions On-demand treatment of HAE attacks with oral sebetralstat was associated with meaningful improvement in AE-QoL 45.2% of participants in KONFIDENT-S achieved a clinically meaningful improvement in LOESS fitted AE-QoL total score The greatest AE-QoL score changes were observed in the domai
Slide 11: Acknowledgments
Acknowledgments • KalVista thanks the people living with HAE and their families, patient advocates, and the investigator teams around the world who supported the KONFIDENT-S clinical trial • Medical writing support was provided under the guidance of the authors by ApotheCom (San Francisco, CA, USA),
KalVista Pharmaceuticals — 2026 HAEi Regional Conference Americas on 6ix